Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 45 of 70 results for lenalidomide

  1. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    In development Reference number: GID-TA11956 Expected publication date:  28 January 2027

    Technology appraisal guidance
    In development

  2. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA763

  3. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

    Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.

    Technology appraisal guidance
    Published
    13 April 2022
    View recommendations

    Sections for TA783

  4. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA658

  5. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

    Technology appraisal guidance
    Published
    24 September 2025

    Sections for TA1098

  6. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

    Technology appraisal guidance
    Published
    23 March 2016
    View recommendations

    Sections for TA386

  7. Non-Hodgkin lymphoma: diagnosis and management (NG52)

    This guideline covers diagnosing, staging and managing non-Hodgkin lymphoma (NHL) in people aged 16 years and over. It includes radiotherapy, systemic anticancer therapy and stem cell transplantation treatments for follicular, MALT, mantle cell, diffuse large B-cell, Burkitt and peripheral T-cell lymphoma.

    NICE guideline
    Published
    20 July 2016
    View recommendations

    Sections for NG52

  8. The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies.

    rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have...

    Research recommendation
    Published
    25 October 2019

  9. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or...

    Research recommendation
    Published
    9 June 2015

  10. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

    Technology appraisal guidance
    Published
    11 March 2026
    View recommendations

    Sections for TA1139

  11. Published guidance, NICE advice and quality standards

    Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards

  12. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued Reference number: GID-TA10308

    Technology appraisal guidance
    Discontinued

  13. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  15. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued